Literature DB >> 12900534

Double resection for patients with pancreatic cancer and a second primary renal cell cancer.

N Alexakis1, L Bosonnet, S Connor, I Ellis, R Sutton, F Campbell, M Hughes, C Garvey, J P Neoptolemos.   

Abstract

BACKGROUND: Reports of synchronous or metachronous double kidney-pancreas cancers are very rare.
METHODS: We present 2 patients with renal cell carcinoma and synchronous (1 patient) or metachronous (1 patient) primary pancreatic ductal adenocarcinoma. The patients underwent resection for both cancer types with a worthwhile outcome.
RESULTS: The appearance of different primaries in an individual may indicate a genetic predisposition to different neoplasms. The study of double primary cancers is important because it might provide understanding of a shared genetic basis of different solid tumors.
CONCLUSIONS: The association between these two cancers demands more detailed epidemiological and molecular investigation. From a clinical viewpoint a resectional policy is recommended. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2003        PMID: 12900534     DOI: 10.1159/000072711

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  3 in total

1.  Renal tumors and second primary pancreatic tumors: a relationship with clinical impact?

Authors:  Sascha A Müller; Sascha Pahernik; Ulf Hinz; David J Martin; Moritz N Wente; Thilo Hackert; Christine Leowardi; Axel Haferkamp; Markus W Büchler; Bruno M Schmied
Journal:  Patient Saf Surg       Date:  2012-08-08

2.  Synchronous Primary Renal Cell Carcinoma and Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review.

Authors:  Tarik Mahfoud; Rachid Tanz; Mohamed Réda Khmamouche; Mohamed Allaoui; Rhizlane Belbaraka; Mouna Khouchani; Mohamed Ichou
Journal:  Case Rep Oncol       Date:  2017-11-27

3.  Second Primary Renal Cell Carcinoma With Nonrenal Malignancies: An Analysis of 118 Cases and a Review of Literature.

Authors:  Jinchao Chen; Nienie Qi; Hua Wang; Zongping Wang; Yedie He; Shaoxing Zhu
Journal:  Front Oncol       Date:  2021-11-25       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.